Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China · Delayed Price · Currency is CNY 35.00
+0.55 (1.60%)
At close: Nov 13, 2026
SHA:603014 Revenue
Shandong Weigao Blood Purification Products had revenue of 2.61B CNY in the quarter ending September 30, 2026, with 168.65% growth. This brings the company's total for the last twelve months to 5.40B, up 46.15% year-over-year. In the year 2025, Shandong Weigao Blood Purification Products had annual revenue of 3.77B with 4.57% growth. That makes Shandong Weigao Blood Purification Products the 8,670th largest company in the world by revenue and 1,336th in China.
Revenue (ttm)
5.40B
Revenue Growth
+46.15%
P/S Ratio
2.71
Revenue / Employee
n/a
Employees
3,734
Market Cap
14.62B
Revenue by Geography
- Mainland China 3.44B 91.3%
- Other Countries and Regions 329.26M 8.7%
Fiscal year ended Dec 31, 2025 See the full SHA:603014 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.77B | 164.70M | 4.57% |
| Dec 31, 2024 | 3.60B | 71.87M | 2.03% |
| Dec 31, 2023 | 3.53B | 106.03M | 3.09% |
| Dec 31, 2022 | 3.43B | 515.59M | 17.71% |
| Dec 31, 2021 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lepu Medical Technology (Beijing) | 6.17B |
| Sinocare | 5.05B |
| Autobio Diagnostics | 4.34B |
| Cofoe Medical Technology | 4.18B |
| Double Medical Technology | 2.80B |
| Qingdao Haier Biomedical Co.,Ltd | 2.53B |
| Jafron Biomedical | 2.07B |
| MeHow Innovative | 1.79B |